2024
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohort
2023
Emerging concepts in the care of patients with cirrhosis and septic shock
Jimenez J, Garcia-Tsao G, Saffo S. Emerging concepts in the care of patients with cirrhosis and septic shock. World Journal Of Hepatology 2023, 15: 497-514. PMID: 37206653, PMCID: PMC10190696, DOI: 10.4254/wjh.v15.i4.497.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCare of patientsSeptic shockLandmark clinical trialsClinical practice guidelinesPathophysiology-based approachChronic hypotensionDecompensated cirrhosisImmunologic disturbancesIntravenous fluidsClinical trialsPractice guidelinesCirrhosisRoutine interventionGeneral populationPatientsLactate metabolismCareHigh rateContext of factorsHypotensionVasopressorsMorbidityPopulationCritical knowledge gapsMortalityMachine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Noureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Garcia‐Tsao G, Harrison S, Chalasani N. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary Pharmacology & Therapeutics 2023, 57: 409-417. PMID: 36647687, PMCID: PMC10107331, DOI: 10.1111/apt.17363.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPresence of varicesEnd of treatmentValidation cohortLiver histology scoresPhase 2b trialPrimary efficacy endpointVenous pressure gradientDevelopment of varicesNonalcoholic steatohepatitis cirrhosisImportant histologic featuresImportant clinical relevanceHVPG changesEfficacy endpointHVPG measurementLiver histologyUpper endoscopyLiver biopsyLiver outcomesHistologic variablesNASH cirrhosisHistologic featuresHypertension assessmentCirrhosis (HALT-C) TrialClinical trials
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrialsOrdinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis
D’Amico G, Abraldes JG, Rebora P, Valsecchi MG, Garcia‐Tsao G. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. Hepatology 2020, 72: 1029-1042. PMID: 31837238, PMCID: PMC11090179, DOI: 10.1002/hep.31070.Peer-Reviewed Original ResearchConceptsClinical trialsGrade 1Prevention of decompensationBaseline platelet countDevelopment of varicesSignificant outcome differencesLow baseline riskPrimary therapeutic targetCirrhosis decompensationCompensated cirrhosisInception cohortComposite endpointEsophageal varicesPlatelet countBinary outcomesDisease progressionSignificant treatment effectBaseline riskGrade 3Sample sizeOutcome differencesTherapeutic targetDecompensationGrade 2Larger sample size
2019
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019, 69: 1287-1299. PMID: 30318607, PMCID: PMC11090176, DOI: 10.1002/hep.30314.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePortal pressurePortal hypertensionLiver diseaseCardiac output leadsCause of cirrhosisCirrhotic portal hypertensionChronic liver diseaseFatty liver diseasePortal venous inflowIntrahepatic vascular resistanceRisk of decompensationEarly clinical studiesCirrhosis decompensationSplanchnic vasodilationVascular resistancePharmacological therapyEtiological treatmentVenous inflowCirrhosis resultsSuch therapyClinical trialsBest therapyClinical studiesCirrhosis
2014
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients
Buck M, Garcia‐Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 2014, 59: 1052-1059. PMID: 24115225, DOI: 10.1002/hep.26755.Peer-Reviewed Original ResearchConceptsHepatic vein pressure gradientGastroesophageal varicesCirrhosis patientsUnnecessary esophagogastroduodenoscopyPortal hypertensionInflammatory biomarkersMultivariate logistic regression analysisInflammatory serum biomarkersNovel inflammatory biomarkerSerum VCAM-1Logistic regression analysisAssociated morbidityCohort studyPortal pressureLiver injuryBlood testsClinical parametersInflammatory pathwaysSerum biomarkersClinical trialsVCAM-1IL-1RPatientsDiagnostic testsMmHg
2011
Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment
Wiest R, Garcia-Tsao G. Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment. Frontiers Of Gastrointestinal Research 2011, 28: 65-82. DOI: 10.1159/000318963.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisAntibiotic prophylaxisHistory of SBPSpontaneous bacterial peritonitis prophylaxisLong-term antibiotic treatmentPrompt effective therapyPrognosis of patientsIdentification of patientsSevere bacterial infectionsLife-threatening infectionsSpontaneous bacteremiaGastrointestinal hemorrhageCirrhotic patientsBacterial peritonitisTreatment failureAntibiotic treatmentClinical trialsCurrent guidelinesEffective therapyFirst episodeHigh riskProphylaxisPatientsBacterial infectionsSpontaneous infectionVasoconstrictor Therapy for Hepatorenal Syndrome
Yeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome. Frontiers Of Gastrointestinal Research 2011, 28: 149-162. DOI: 10.1159/000318997.Peer-Reviewed Original ResearchHepatorenal syndromeReceptor agonistClinical trialsEffective arterial blood volumeType 2 hepatorenal syndromeAlpha-adrenergic receptor agonistIschemic adverse eventsNeurohormonal system activationPreferred alternative therapyRenal function effectsFirst-line therapyMain pathogenic mechanismRandomized clinical trialsAdrenergic receptor agonistArterial blood volumeVasopressin receptor agonistSuboptimal study designEase of administrationOral midodrineRenal vasoconstrictionSystemic vasodilatationVasoconstrictor therapyDefinitive therapyIntravenous albuminKidney injury
2007
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States
Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia‐Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B, Group P. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007, 46: 769-775. PMID: 17654740, PMCID: PMC4167731, DOI: 10.1002/hep.21759.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisNon-Caucasian patientsChronic cholestatic liver diseaseCholestatic liver diseaseLiver diseaseDisease severityBiliary cirrhosisClinical presentationClinical trialsAntimitochondrial antibody (AMA) statusLiver disease severityMiddle-aged Caucasian womenMulticenter clinical trialGreater disease severityAfrican AmericansAdvanced diseaseSerologic featuresSevere pruritusAntibody statusHispanic patientsAMA positivityMean ageFemale ratioPhysical findingsCaucasian women
1989
Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial
Bosch J, Groszmann R, García‐Pagán J, Terés J, García‐Tsao G, Navasa M, Mas A, Rodés J. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial. Hepatology 1989, 10: 962-968. PMID: 2511136, DOI: 10.1002/hep.1840100612.Peer-Reviewed Original ResearchConceptsTransdermal nitroglycerinVariceal hemorrhageVariceal bleedingPlacebo-controlled clinical trialActive variceal bleedingEffectiveness of vasopressinDouble-blind techniqueSlow-release preparationHospital mortalityTransfusion requirementsRecurrent bleedingBalloon tamponadeCirrhotic patientsEmergency surgeryVasopressin infusionClinical trialsDefinitive controlDrug combinationsTotal doseNitroglycerinBleedingHemorrhagePatientsInitial controlVasopressin